Results 61 to 70 of about 6,220 (214)

Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment

open access: yesPediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Introduction Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The pro‐drug 6‐mercaptopurine (6‐MP), essential during maintenance, is converted into active 6‐thioguanine (6‐TGN) and toxic 6‐methylmercaptopurine (6‐MMP) metabolites, resulting in marked variability in efficacy and toxicity.
Anne Ravix   +5 more
wiley   +1 more source

Azathioprine-Induced Peripheral T Cell Apoptosis And Drug Response In Patients With Crohn’s Disease [PDF]

open access: yes, 2011
Background and Aim: the long time interval for a trial of thioupurine therapy and the potential side effects in spite of the proven efficacy, do not encourage their use as early therapeutic option in Crohn’s Disease (CD).
Cossu, Andrea
core  

Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis

open access: yesCancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background Pharmacovigilance has revealed an alarming correlation between certain medications and a higher risk of cancer. In this narrative review, included research from 2020 to 2025, along with a few seminal older studies, so that it provides a clear picture of which drugs actually set off cancer and mechanisms involved at the molecular ...
Desta Seyoum Tadesse   +5 more
wiley   +1 more source

A Rapid and Reliable Absorbance Assay to Identify Drug–Drug Interactions with Thiopurine Drugs

open access: yesMetabolites
Background: Thiopurine methyltransferase (TPMT) plays a crucial role in the detoxification of thiopurine drugs, including the antimetabolites azathioprine and 6-mercaptopurine (6-MP) used to treat autoimmune diseases and various cancers.
Drake A. Russell   +2 more
doaj   +1 more source

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. [PDF]

open access: yesPLoS ONE, 2014
Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40-60% of cancer patients. It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT ...
Melanie M Hagleitner   +10 more
doaj   +1 more source

Case Report: Azathioprine: An Old and Wronged Immunosuppressant

open access: yesFrontiers in Immunology, 2022
Mycophenolate rapidly substituted azathioprine (AZA) in transplant immunosuppression regimens since the 1990s, when early clinical trials indicated better outcomes, although opposite results were also observed. However, none of these trials used the well-
Pedro R. Chocair   +10 more
doaj   +1 more source

Structural term extraction for expansion of template-based genomic queries [PDF]

open access: yes, 2005
This paper describes our experiments run to address the ad hoc task of the TREC 2005 Genomics track. The task topics were expressed with 5 different structures called Generic Topic Templates (GTTs). We hypothesized the presence of GTT-specific structural
Blott, Stephen   +4 more
core  

Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD

open access: yesTherapeutic Advances in Gastroenterology, 2017
Background: Thiopurines, azathioprine (AZA) and 6-mercaptopurine (6-MP) are common maintenance medications for inflammatory bowel disease (IBD).
Brigitte Moreau   +3 more
doaj   +1 more source

Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia [PDF]

open access: yes, 2011
Predicting the response to medical therapy and subsequently individualizing the treatment to increase efficacy or reduce toxicity has been a longstanding clinical goal.
Jacob Nersting   +2 more
core   +3 more sources

Pharmacogenetics of thiopurine therapy: from thiopurine S-methyltransferase to S-adenosylmethionine [PDF]

open access: yesBMC Pharmacology, 2009
Background The efficiency and safety of the thiopurine therapy rely on the concentration of patient’s cytotoxic thioguanine nucleotides (TGN), which in turn depend on the deactivation of thiopurine drugs by thiopurine S-methyltransferase (TPMT). The activity of TPMT largely depends on the presence of genetic polymorphisms. Determination of mutations in
Mlinarič-Raščan, Irena   +2 more
openaire   +1 more source

Home - About - Disclaimer - Privacy